

NCT03338855 Raw comparison:

Summary:
CHIA has 28 criteria while your personal folder has 31 criteria
Total found criteria: 23/28
Total not Found: 5/28
Total Extra: 3
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Involvement in the planning and conduct of the     │ Involvement in the planning and conduct of the     │
│ study (applies to both AstraZeneca staff and staff │ study (applies to both AstraZeneca staff and staff │
│ at third party vendor or at the investigational    │ at third party vendor or at the investigational    │
│ sites)                                             │ sites)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous enrolment in the present study or         │ Previous enrolment in the present study or         │
│ participation in another clinical study with an    │ participation in another clinical study with an    │
│ investigational product during the last 3 months   │ investigational product during the last 3 months   │
│ or as judged by the Investigator                   │ or as judged by the Investigator                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of or presence of any clinically           │ History of or presence of any clinically           │
│ significant disease or disorder including a recent │ significant disease or disorder including a recent │
│ (< 3 months) cardiovascular event which in the     │ (\< 3 months) cardiovascular event which in the    │
│ opinion of the Investigator may either put the     │ opinion of the Investigator may either put the     │
│ patient at risk because of participation in the    │ patient at risk because of participation in the    │
│ study or influence the results or the patient's    │ study or influence the results or the patient's    │
│ ability to participate in the study                │ ability to participate in the study                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinical diagnosis of Type 1 diabetes maturity     │ Clinical diagnosis of Type 1 diabetes maturity     │
│ onset diabetes of the young secondary diabetes or  │ onset diabetes of the young secondary diabetes or  │
│ diabetes insipidus                                 │ diabetes insipidus                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unstable/rapidly progressing renal disease or      │ Unstable/rapidly progressing renal disease or      │
│ estimated Glomerular Filtration Rate < 60 mL/min   │ estimated Glomerular Filtration Rate \< 60 mL/min  │
│ (Cockcroft-Gault formula)                          │ (Cockcroft-Gault formula)                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant out of range values of      │ Clinically significant out of range values of      │
│ serum levels of either alanine aminotransferase    │ serum levels of either alanine aminotransferase    │
│ (ALT) aspartate aminotransferase (AST) or alkaline │ (ALT) aspartate aminotransferase (AST) or alkaline │
│ phosphatase (ALP) in the Investigator's opinion    │ phosphatase (ALP) in the Investigator's opinion    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contraindications to dapagliflozin according to    │ Contraindications to dapagliflozin according to    │
│ the local label                                    │ the local label                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of antidiabetic drugs other than metformin     │ Use of antidiabetic drugs other than metformin     │
│ within 3 months prior to screening                 │ within 3 months prior to screening                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Weight gain or loss > 5 kg in the last 3 months    │ Weight gain or loss \> 5 kg in the last 3 months   │
│ ongoing weight-loss diet (hypocaloric diet) or use │ ongoing weight-loss diet (hypocaloric diet) or use │
│ of weight loss agents                              │ of weight loss agents                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of drug abuse or alcohol abuse in the past │ History of drug abuse or alcohol abuse in the past │
│ 12 months                                          │ 12 months                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any clinically significant abnormalities in        │ Any clinically significant abnormalities in        │
│ clinical chemistry hematology or urinalysis or     │ clinical chemistry hematology or urinalysis or     │
│ other condition the Investigator believes would    │ other condition the Investigator believes would    │
│ interfere with the patient's ability to provide    │ interfere with the patient's ability to provide    │
│ informed consent comply with study instructions or │ informed consent comply with study instructions or │
│ which might confound the interpretation of the     │ which might confound the interpretation of the     │
│ study results or put the patient at undue risk     │ study results or put the patient at undue risk     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Plasma donation within one month of screening or   │ Plasma donation within one month of screening or   │
│ any blood donation/blood loss > 500 mL within 3    │ any blood donation/blood loss \> 500 mL within 3   │
│ months prior to screening or during the study      │ months prior to screening or during the study      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Anemia defined as Hemoglobin (Hb) < 115 g/L (7 1   │ Anemia defined as Hemoglobin (Hb) \< 115 g/L (7 1  │
│ mM) in women and < 120 g/L (7 5 mM) in men         │ mM) in women and \< 120 g/L (7 5 mM) in men        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of anti-coagulant treatment such as heparin    │ Use of anti-coagulant treatment such as heparin    │
│ warfarin platelet inhibitors thrombin and factor X │ warfarin platelet inhibitors thrombin and factor X │
│ inhibitors                                         │ inhibitors                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of medication such as oral glucocorticoids     │ Use of medication such as oral glucocorticoids     │
│ anti-estrogens or other medications that are known │ anti-estrogens or other medications that are known │
│ to markedly influence insulin sensitivity          │ to markedly influence insulin sensitivity          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of loop diuretics                              │ Use of loop diuretics                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Regular smoking and other regular nicotine use     │ Regular smoking and other regular nicotine use     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Central nervous system aneurysm clip               │ Central nervous system aneurysm clip               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Implanted neural stimulator                        │ Implanted neural stimulator                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Implanted cardiac pacemaker of defibrillator       │ Implanted cardiac pacemaker of defibrillator       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cochlear implant                                   │ Cochlear implant                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Metal containing corpora aliena in the eye or      │ Metal containing corpora aliena in the eye or      │
│ brain                                              │ brain                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who do not want to be informed about      │ Patients who do not want to be informed about      │
│ unexpected medical findings or do not wish that    │ unexpected medical findings or do not wish that    │
│ their physician be informed about coincidental     │ their physician be informed about coincidental     │
│ findings cannot participate in the study           │ findings cannot participate in the study           │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                 │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Patients are able to provide signed and dated written informed consent prior to any study specific  │
│ procedures                                                                                          │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Women are post-menopausal (defined as at least 1 year post cessation of menses) and aged = 45 and = │
│ 70 years Males are aged = 40 years and = 70 years Patients should have suitable veins for           │
│ cannulation or repeated venipuncture                                                                │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients are diagnosed with T2DM for at least the last 6 months                                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients are on no other anti-diabetic drug treatment or on stable maximum 3000 mg daily dose       │
│ metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3    │
│ months5 HbA1c levels =6 0% (=42 mmol/mol) and =9 0% (75 mmol/mol)                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Have a body mass index (BMI) = 35 kg/m2                                                             │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                       │
╞═══════════════════════════════════════════════════════════════════════════════════════════════╡
│ Any contra-indication to magnetic resonance imaging scanning These contra-indications include │
│ patients with following devices                                                               │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 70 Years                                                             │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 40 Years                                                             │
╘═══════════════════════════════════════════════════════════════════════════════════════════════╛